Analysis of efficacy and safety of dulaglutide 0.75 mg stratified by sex in patients with type 2 diabetes in 2 randomized, controlled phase 3 studies in Japan.

Onishi Y, Oura T, Matsui A, Matsuura J, Iwamoto N

Endocrine journal29 Mar 2017Cited by 36 (Europe PMC)

PMID28367916DOI10.1507/endocrj.ej16-0552PepBankPUB-28367916

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

1 result from studies that gave the peptide. 1 result from people.

01HumanRandomized controlled trialSafety outcome
In Japanese patients with type 2 diabetes, fewer than 10% of each sex discontinued dulaglutide early because of adverse events.
In plain wordsFewer than 10% of women and men stopped dulaglutide early because of adverse events.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableDiscontinuation due to adverse events
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
0.75 mg once weeklyAs given in this study (human).
Measurements
Discontinuation due to adverse events
< 10%
each sex receiving dulaglutide
Source sentences
Summary
Incidences of patients discontinuing dulaglutide early due to adverse event were low (<10%) for both sexes, and no new safety concerns related to dulaglutide were identified for either sex.
1 context sentence(design, population, supporting numbers)
Summary · context
We analyzed the efficacy and safety of once weekly dulaglutide 0.75 mg by sex in 2 randomized, controlled phase 3 studies in Japanese patients with type 2 diabetes (a 52-week monotherapy study [comparator liraglutide 0.9 mg] and a 26-week combination therapy study [comparator insulin glargine]).
Report a problemFND-2836791612

Studies that did not test the peptide alone11

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

02HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In Japanese adults with type 2 diabetes, HbA1c reductions were similar between the sexes in patients treated with dulaglutide or liraglutide.
In plain wordsIn Japanese adults with type 2 diabetes, women and men had similar HbA1c drops on dulaglutide or liraglutide.
Peptide
Liraglutide
Outcome
No significant changeHbA1c reduction by sex
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Mean reductions from baseline in glycated hemoglobin (HbA1c) were similar between the sexes for dulaglutide- and liraglutide-treated patients (range -1.17% to -1.49%).
1 context sentence(design, population, supporting numbers)
Summary · context
We analyzed the efficacy and safety of once weekly dulaglutide 0.75 mg by sex in 2 randomized, controlled phase 3 studies in Japanese patients with type 2 diabetes (a 52-week monotherapy study [comparator liraglutide 0.9 mg] and a 26-week combination therapy study [comparator insulin glargine]).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2836791601
03HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In Japanese adults with type 2 diabetes, females had numerically greater weight loss or less weight gain than males across all treatment groups, including dulaglutide, liraglutide and insulin glargine.
In plain wordsIn Japanese adults with type 2 diabetes, women lost more weight, or gained less, than men across all treatment groups.
Peptide
Liraglutide
Outcome
Not applicableWeight change by sex
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Females had numerically greater weight loss or less weight gain than males across all treatment groups.
1 context sentence(design, population, supporting numbers)
Summary · context
We analyzed the efficacy and safety of once weekly dulaglutide 0.75 mg by sex in 2 randomized, controlled phase 3 studies in Japanese patients with type 2 diabetes (a 52-week monotherapy study [comparator liraglutide 0.9 mg] and a 26-week combination therapy study [comparator insulin glargine]).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2836791602
04HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In Japanese adults with type 2 diabetes, the percentage of patients with reductions in both HbA1c and weight was greater for females than for males in all treatment groups.
In plain wordsIn Japanese adults with type 2 diabetes, more women than men had both lower HbA1c and lower weight across all treatment groups.
Peptide
Liraglutide
Outcome
Not applicableReduction in both HbA1c and weight by sex
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
The percentages of patients with reductions in both HbA1c and weight from baseline were also greater for females than for males in all treatment groups.
1 context sentence(design, population, supporting numbers)
Summary · context
We analyzed the efficacy and safety of once weekly dulaglutide 0.75 mg by sex in 2 randomized, controlled phase 3 studies in Japanese patients with type 2 diabetes (a 52-week monotherapy study [comparator liraglutide 0.9 mg] and a 26-week combination therapy study [comparator insulin glargine]).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2836791603
05HumanNot a test of Liraglutide aloneRandomized controlled trialSafety outcome
In Japanese adults with type 2 diabetes, treatment-emergent adverse events tended to be more frequent in females than in males across all treatment groups.
In plain wordsIn Japanese adults with type 2 diabetes, side effects tended to be more common in women than in men across all treatment groups.
Peptide
Liraglutide
Outcome
Not applicableTreatment-emergent adverse events by sex
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Source sentences
Summary
In all treatment groups, the incidences of treatment-emergent adverse events tended to be greater among females than among males.
1 context sentence(design, population, supporting numbers)
Summary · context
We analyzed the efficacy and safety of once weekly dulaglutide 0.75 mg by sex in 2 randomized, controlled phase 3 studies in Japanese patients with type 2 diabetes (a 52-week monotherapy study [comparator liraglutide 0.9 mg] and a 26-week combination therapy study [comparator insulin glargine]).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2836791604
06HumanNot a test of Liraglutide aloneRandomized controlled trialSafety outcome
In Japanese adults with type 2 diabetes, total and nocturnal hypoglycemia incidences did not differ between the sexes in any treatment group.
In plain wordsIn Japanese adults with type 2 diabetes, low blood sugar events were equally common in women and men in every treatment group.
Peptide
Liraglutide
Outcome
No significant changeHypoglycemia incidence by sex
Study
n: not reported in source
Outcome group
Adverse events · Metabolic and weight
Source sentences
Summary
No differences in the incidences of total or nocturnal hypoglycemia were observed between the sexes in any treatment group.
1 context sentence(design, population, supporting numbers)
Summary · context
We analyzed the efficacy and safety of once weekly dulaglutide 0.75 mg by sex in 2 randomized, controlled phase 3 studies in Japanese patients with type 2 diabetes (a 52-week monotherapy study [comparator liraglutide 0.9 mg] and a 26-week combination therapy study [comparator insulin glargine]).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2836791605
07HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In Japanese patients with type 2 diabetes receiving dulaglutide or liraglutide, HbA1c reductions were similar between sexes.
In plain wordsHbA1c reductions were similar between women and men receiving dulaglutide or liraglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
Direction not reportedHbA1c reduction by sex
Study
n: not reported in source
Comparator
Male patients
Outcome group
Glycemic control · Metabolic and weight
Measurements
Mean HbA1c reduction from baseline
−1.49 to −1.17%
dulaglutide- and liraglutide-treated patients, both sexes
Source sentences
Summary
Mean reductions from baseline in glycated hemoglobin (HbA1c) were similar between the sexes for dulaglutide- and liraglutide-treated patients (range -1.17% to -1.49%).
1 context sentence(design, population, supporting numbers)
Summary · context
We analyzed the efficacy and safety of once weekly dulaglutide 0.75 mg by sex in 2 randomized, controlled phase 3 studies in Japanese patients with type 2 diabetes (a 52-week monotherapy study [comparator liraglutide 0.9 mg] and a 26-week combination therapy study [comparator insulin glargine]).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2836791606
08HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In Japanese patients with type 2 diabetes, females showed numerically greater weight loss or less gain across all treatment groups.
In plain wordsWomen showed numerically greater weight loss or less gain than men across all treatment groups, including dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseBody weight change by sex
Study
n: not reported in source
Comparator
Male patients
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Females had numerically greater weight loss or less weight gain than males across all treatment groups.
1 context sentence(design, population, supporting numbers)
Summary · context
We analyzed the efficacy and safety of once weekly dulaglutide 0.75 mg by sex in 2 randomized, controlled phase 3 studies in Japanese patients with type 2 diabetes (a 52-week monotherapy study [comparator liraglutide 0.9 mg] and a 26-week combination therapy study [comparator insulin glargine]).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2836791607
09HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In Japanese patients with type 2 diabetes, concurrent HbA1c and weight reductions were more frequent among females across all treatment groups.
In plain wordsConcurrent blood sugar and weight reductions were more frequent among women than men across all treatment groups, including dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseConcurrent HbA1c and weight reduction by sex
Study
n: not reported in source
Comparator
Male patients
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
The percentages of patients with reductions in both HbA1c and weight from baseline were also greater for females than for males in all treatment groups.
1 context sentence(design, population, supporting numbers)
Summary · context
We analyzed the efficacy and safety of once weekly dulaglutide 0.75 mg by sex in 2 randomized, controlled phase 3 studies in Japanese patients with type 2 diabetes (a 52-week monotherapy study [comparator liraglutide 0.9 mg] and a 26-week combination therapy study [comparator insulin glargine]).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2836791608
10HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
In Japanese patients with type 2 diabetes, treatment-emergent adverse events tended to be more frequent among females across all treatment groups.
In plain wordsAdverse events tended to be more frequent among women than men across all treatment groups, including dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseTreatment-emergent adverse events by sex
Study
n: not reported in source
Comparator
Male patients
Outcome group
Adverse events · Whole body
Source sentences
Summary
In all treatment groups, the incidences of treatment-emergent adverse events tended to be greater among females than among males.
1 context sentence(design, population, supporting numbers)
Summary · context
We analyzed the efficacy and safety of once weekly dulaglutide 0.75 mg by sex in 2 randomized, controlled phase 3 studies in Japanese patients with type 2 diabetes (a 52-week monotherapy study [comparator liraglutide 0.9 mg] and a 26-week combination therapy study [comparator insulin glargine]).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2836791609
11HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
In Japanese patients with type 2 diabetes, total hypoglycemia incidence did not differ between sexes in any treatment group.
In plain wordsTotal low blood sugar incidence did not differ between women and men in any treatment group, including dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeTotal hypoglycemia by sex
Study
n: not reported in source
Comparator
Male patients
Outcome group
Adverse events · Metabolic and weight
Source sentences
Summary
No differences in the incidences of total or nocturnal hypoglycemia were observed between the sexes in any treatment group.
1 context sentence(design, population, supporting numbers)
Summary · context
We analyzed the efficacy and safety of once weekly dulaglutide 0.75 mg by sex in 2 randomized, controlled phase 3 studies in Japanese patients with type 2 diabetes (a 52-week monotherapy study [comparator liraglutide 0.9 mg] and a 26-week combination therapy study [comparator insulin glargine]).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2836791610
12HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
In Japanese patients with type 2 diabetes, nocturnal hypoglycemia incidence did not differ between sexes in any treatment group.
In plain wordsNighttime low blood sugar incidence did not differ between women and men in any treatment group, including dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeNocturnal hypoglycemia by sex
Study
n: not reported in source
Comparator
Male patients
Outcome group
Adverse events · Metabolic and weight
Source sentences
Summary
No differences in the incidences of total or nocturnal hypoglycemia were observed between the sexes in any treatment group.
1 context sentence(design, population, supporting numbers)
Summary · context
We analyzed the efficacy and safety of once weekly dulaglutide 0.75 mg by sex in 2 randomized, controlled phase 3 studies in Japanese patients with type 2 diabetes (a 52-week monotherapy study [comparator liraglutide 0.9 mg] and a 26-week combination therapy study [comparator insulin glargine]).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2836791611

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 4 to 8Current
28 Oct 2026, 02:03 UTC
The same notice was added 5 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.
Study results updated
Version 3
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 2
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.